Division of Dermatology, McGill University Health Centre, Montreal, Quebec, Canada.
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
JAMA Dermatol. 2017 Dec 1;153(12):1236-1242. doi: 10.1001/jamadermatol.2017.3182.
Chronic urticaria (CU) affects 0.1% to 0.3% of children. Most cases have no identifiable trigger and are classified as chronic spontaneous urticaria (CSU). At least half of patients with CSU may have an autoimmune etiology that can be determined in vitro using the basophil activation test (BAT). While 30% to 55% of CU cases resolve spontaneously within 5 years in adults, the natural history and predictors of resolution in children are not known.
To assess the comorbidities, natural history of CU, and its subtypes in children and identify predictors of resolution.
DESIGN, SETTING, AND PARTICIPANTS: We followed a pediatric cohort with chronic urticaria that presented with hives lasting at least 6 weeks between 2013 and 2015 at a single tertiary care referral center.
Data were collected on disease activity, comorbidities, physical triggers, BAT results, complete blood cell count, C-reactive protein levels, thyroid-stimulating hormone levels, and thyroid peroxidase antibodies.
We assessed the rate of resolution (defined as absence of hives for at least 1 year with no treatment) and the association with clinical and laboratory markers.
The cohort comprised 139 children younger than 18 years old. Thirty-one patients (20%) had inducible urticaria, most commonly cold induced. Six children had autoimmune comorbidity, such as thyroiditis and type 1 diabetes. Autoimmune disorders (24 patients [17%]) and CU (17 patients [12%]) were common in family members. Positive BAT results (CD63 levels > 1.8%) were found in 58% of patients. Patients with positive BAT results (CD63 level >1.8%) were twice as likely to resolve after 1 year compared with negative BAT results (hazard ratio [HR], 2.33; 95% CI, 1.08-5.05). In contrast, presence of basophils decreased the likelihood of resolution (HR, 0.40; 95% CI, 0.20-0.99). No correlation with age was found. Chronic urticaria resolved in 43 patients, with a rate of resolution of 10.3% per year. Levels of CD63 higher than 1.8% and absence of basophils were associated with earlier disease resolution.
Resolution rate in children with CU is low. The presence of certain biomarkers (positive BAT result and basophil count) may help to predict the likelihood of resolution.
慢性荨麻疹(CU)影响 0.1%至 0.3%的儿童。大多数病例没有可识别的诱因,被归类为慢性自发性荨麻疹(CSU)。至少一半的 CSU 患者可能存在自身免疫病因,这可以通过体外使用嗜碱性粒细胞激活试验(BAT)来确定。虽然成年人中 30%至 55%的 CU 病例在 5 年内自发缓解,但儿童的自然病史和缓解预测因素尚不清楚。
评估儿童 CU 的合并症、自然病史及其亚型,并确定缓解的预测因素。
设计、地点和参与者:我们对 2013 年至 2015 年间在一家三级转诊中心就诊的至少持续 6 周的慢性荨麻疹患儿进行了慢性荨麻疹队列研究。
收集疾病活动度、合并症、物理诱因、BAT 结果、全血细胞计数、C 反应蛋白水平、促甲状腺激素水平和甲状腺过氧化物酶抗体等数据。
我们评估了缓解率(定义为至少 1 年无治疗且无荨麻疹)与临床和实验室标志物的相关性。
该队列包括 139 名年龄小于 18 岁的儿童。31 名患者(20%)有诱导性荨麻疹,最常见的是冷诱导性荨麻疹。6 名儿童有自身免疫性合并症,如甲状腺炎和 1 型糖尿病。自身免疫性疾病(24 名患者[17%])和 CU(17 名患者[12%])在家庭成员中很常见。58%的患者 BAT 结果(CD63 水平>1.8%)阳性。与 BAT 结果阴性的患者相比,BAT 结果阳性(CD63 水平>1.8%)的患者在 1 年后缓解的可能性是其两倍(风险比[HR],2.33;95%CI,1.08-5.05)。相反,嗜碱性粒细胞的存在降低了缓解的可能性(HR,0.40;95%CI,0.20-0.99)。与年龄无相关性。43 名慢性荨麻疹患儿缓解,缓解率为每年 10.3%。CD63 水平高于 1.8%和嗜碱性粒细胞计数低与疾病更早缓解相关。
儿童 CU 的缓解率较低。某些生物标志物(阳性 BAT 结果和嗜碱性粒细胞计数)的存在可能有助于预测缓解的可能性。